supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months

August 2012

You'll see supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months.

It's not a drug shortage. Lepirudin is being discontinued by the manufacturer for business reasons...not safety concerns.

This leaves just one first-line agent for preventing and treating thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote